Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company Immunomedics Inc.
DescriptionHumanized mAb targeting major histocompatibility complex (MHC) class II DR (HLA-DR) fused to an amphibian RNase using dock and lock (DNL) conjugation technology
Molecular Target Major histocompatibility complex class II DR (HLA-DR)
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPreclinical
Standard IndicationAcute lymphoblastic leukemia (ALL)
Indication DetailsTreat acute lymphoblastic leukemia (ALL)
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today